2023 (23 POSTS)

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. Hospitalizations, clinical characteristics and mortality in adults with adrenomyeloneuropathy (AMN): A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258.

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, Liu Y, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcome Res 23(2):225-230; doi: 10.1080/14737167.2023.2160705. PMID: 36537696.

View Abstract

2022 (12 POSTS)

Cardosi L, Rau R, Emdem MR, Kemp R, Minshall M, Pontenani F, Provision S, Sacks N. 2022. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Value in Health 25(12):S89-S90; doi: 10.1016/j.jval.2022.09.437.

View Abstract

Jensen I, Cyr P. 2022. Early health economic models in gene and cell therapy to inform clinical trial design and optimize commercialization efforts. White Paper. PharmaLive.

Yao W, Jensen I, Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi:  10.5863/1551-6776-27.8.695.

View Abstract

Pang F, Dean R, Jensen I, Tehard B, Roze S, Olaye A, et al. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Abstract EE24, ISPOR 2022.

View Abstract

Habib A, Sacks NC, Cool C, Durgapal S, Hughes T, Hernandez J, Phillips G. Trends in hospital admissions and readmissions for patients with MG from U.S. national research databases. Poster presentation, American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, September 2022.

Sacks NC. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Poster presentation, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe, November 2022.

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9. PMID: 34331235.

View Abstract

Alexander AW, Jensen IJ, Hathaway J, Srivastava K, Cyr PL, Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197. PMID: 35343812.

View Abstract

Sacks NC, Healey BE, Raza S, Cyr PL, Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576; doi: 10.1182/bloodadvances.2021004364. PMID: 34807973.

View Abstract

Sheshadri A, Sacks NC, Healey B, Cyr P, Boerner G, Huang HJ. 2022. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States. J Med Econ 25(1):650–659; doi: 10.1080/13696998.2022.2071065. PMID: 35502563.

View Abstract

Sheshadri A, Sacks NC, Healey BE, Raza S, Boerner G, Huang HJ. 2022. Lung function monitoring after lung transplantation and allogeneic hematopoietic stem cell transplantation. Clin Ther 44(5):755–765; doi: 10.1016/j.clinthera.2022.03.011. PMID: 35513911.

View Abstract

Pang F, Dean R, Jensen I, Tehard B, Roze S, Olaye A, et al. 2022. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy in France. Mol Gene Metab 135(2):S93; doi: 10.1016/j.ymgme.2021.11.242.

2021 (15 POSTS)

Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC, Lang K, Nelson WW. 2021. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 9:2050312120986733; doi: 10.1177/2050312120986733. PMID: 33505698.

View Abstract

Sacks NC, Healey BE, Cyr PL, Slocomb T, James E, Beggs AH, Graham RJ. 2021. Costs and health resource use in patients with X-linked myotubular myopathy: insights from U.S. commercial claims. J Manag Care Spec Pharm 27(8):1019–1026; doi: 10.18553/jmcp.2021.20501.

View Abstract

Dougherty C, Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N, Kautz S, Cyr P. Impact of INP104 on healthcare resource use among patients in STOP 301. Presentation at American Academy of Neurology Annual Meeting, Virtual, April 2021.

Dougherty C, Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N, Kautz S, Cyr P. INP104 reduces self-reported ED and urgent care in patients with episodic migraine. Presentation at Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Virtual, April 2021.

Sheshadri A, Sacks NC, Healey B, Raza S, Cyr P, Boerner G, Huang HJ. A descriptive analysis of costs and healthcare resource use in patients with bronchiolitis obliterans syndrome (BOS) following lung transplantation. Poster presentation, ISPOR 25th Annual International Meeting, May 2021.